{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:37:51Z","timestamp":1787071071629,"version":"build-2736575974"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy, is an autoimmune disorder caused due to a complex interplay between autoantigens including the thyroid-stimulating hormone receptor and the insulin-like growth factor-I receptor. TED is characterized by progressive proptosis or diplopia. This systematic review aimed to compare the efficacy of the newer monoclonal antibody \u2013 teprotumumab and intravenous methylprednisolone (IVMP) in TED patients. We performed a systematic review of previously published studies from 2013 to June 2023. A total of 329 articles were screened; among them, 111 non-duplicate publications were identified. After the screening of titles and abstracts, 156 publications were excluded; then, another 47 published papers were excluded after the full-text screening. The remaining 15 eligible studies were included in this systematic review. The majority of studies used either teprotumumab alone or in combination with others. Among 15 studies, eight studies used teprotumumab in TED patients, whereas remaining 7 studies used a standard treatment regimen. This systematic review provides an overview of the existing treatment options using monoclonal antibody \u2013 teprotumumab and IVMP in TED patients. The overall assessment provides a finding that antibody \u2013 teprotumumab is is a good choice compared to conventional IVMP for providing better outcomes in patients with TED.<\/jats:p>","DOI":"10.4103\/ojo.ojo_308_23","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:14:47Z","timestamp":1730294087000},"page":"313-319","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Teprotumumab versus intravenous methylprednisolone in thyroid eye disease: A systematic review"],"prefix":"10.4103","volume":"17","author":[{"given":"Faizan","family":"Mehmood","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Aster Hospital Al Qusais, Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Ali Raza","family":"Rizvi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Oculoplasty and Ocular Oncology Services, Al Nahdha Hospital, Ministry of Health, Muscat, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Alam","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Canadian Specialist Hospital, Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benazir","family":"Ansari","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Aster DM Healthcare, Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"R1-20241030","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2147\/TCRM.S303057","article-title":"Efficacy and safety of teprotumumab in thyroid eye disease","volume":"17","author":"Teo","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"R2-20241030","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves'ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"R3-20241030","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves'orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"R4-20241030","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves'Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves'orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"R5-20241030","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.4103\/ijo.IJO_2386_20","article-title":"Medical management of thyroid eye disease \u2013A paradigm shift","volume":"68","author":"Honavar","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R6-20241030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13044-020-00086-7","article-title":"Teprotumumab:A disease modifying treatment for graves'orbitopathy","volume":"13","author":"Ting","year":"2020","journal-title":"Thyroid Res"},{"key":"R7-20241030","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"R8-20241030","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/IOP.0000000000001292","article-title":"Bony orbital volume expansion in thyroid eye disease","volume":"35","author":"Ugradar","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R9-20241030","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jamaophthalmol.2021.6284","article-title":"Proptosis and diplopia response with teprotumumab and placebo versus the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease:A meta-analysis and matching-adjusted indirect comparison","volume":"140","author":"Douglas","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"R10-20241030","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.3390\/jcm12093244","article-title":"Efficacy and safety of 6-weekly versus 12-weekly intravenous methylprednisolone in moderate-to-severe active thyroid-associated ophthalmopathy","volume":"12","author":"Lai","year":"2023","journal-title":"J Clin Med"},{"key":"R11-20241030","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaophthalmol.2018.0806","article-title":"Association of T and B cells infiltrating orbital tissues with clinical features of graves orbitopathy","volume":"136","author":"Rotondo Dottore","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R12-20241030","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves'orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med"},{"key":"R13-20241030","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Clinical review:Intravenous glucocorticoids for graves'orbitopathy:Efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20241030","first-page":"3562","article-title":"Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe graves'ophthalmopathy:Results of a prospective, single-blind, randomized study","volume":"86","author":"Marcocci","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-20241030","doi-asserted-by":"crossref","first-page":"1061076","DOI":"10.3389\/fnmol.2022.1061076","article-title":"Extracellular vesicles in neurodegenerative diseases:A systematic review","volume":"15","author":"Raghav","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"R16-20241030","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamaophthalmol.2021.6376","article-title":"Teprotumumab versus intravenous methylprednisolone for thyroid eye disease:Is there still a role for steroids?","volume":"140","author":"Campbell","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"R17-20241030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41433-018-0315-9","article-title":"Interruption of autoimmunity for thyroid eye disease:B-cell and T-cell strategy","volume":"33","author":"Strianese","year":"2019","journal-title":"Eye (Lond)"},{"key":"R18-20241030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/bjophthalmol-2020-316051","article-title":"Medical treatment in thyroid eye disease in 2020","volume":"105","author":"Khong","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"R19-20241030","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00417-023-06013-4","article-title":"Early response to intravenous methylprednisolone therapy for restrictive myopathy in patients with thyroid eye disease","volume":"261","author":"Jang","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R20-20241030","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1210\/clinem\/dgac168","article-title":"Teprotumumab and the evolving therapeutic landscape in thyroid eye disease","volume":"107","author":"Kossler","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-20241030","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41433-018-0321-y","article-title":"Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease:A focus on proptosis","volume":"33","author":"Douglas","year":"2019","journal-title":"Eye (Lond)"},{"key":"R22-20241030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11940-021-00675-3","article-title":"Current management of thyroid eye disease","volume":"23","author":"Mahoney","year":"2021","journal-title":"Curr Treat Options Neurol"},{"key":"R23-20241030","first-page":"36","article-title":"Teprotumumab (Tepezza) for thyroid eye disease","volume":"119","author":"Couch","year":"2022","journal-title":"Mo Med"},{"key":"R24-20241030","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/ICU.0000000000000203","article-title":"Current trends in the management of thyroid eye disease","volume":"26","author":"Rao","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"key":"R25-20241030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/bjophthalmol-2020-317806","article-title":"Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease","volume":"106","author":"Jain","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R26-20241030","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s40265-022-01804-1","article-title":"Teprotumumab:A review in thyroid eye disease","volume":"82","author":"Nie","year":"2022","journal-title":"Drugs"},{"key":"R27-20241030","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/WNO.0000000000001134","article-title":"Teprotumumab in clinical practice:Recommendations and considerations from the OPTIC trial investigators","volume":"41","author":"Douglas","year":"2021","journal-title":"J Neuroophthalmol"},{"key":"R28-20241030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/tjo.tjo_59_21","article-title":"Subcutaneous tocilizumab for active thyroid eye disease refractory to orbital radiation and systemic steroids in tobacco smokers","volume":"12","author":"Stevens","year":"2022","journal-title":"Taiwan J Ophthalmol"},{"key":"R29-20241030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0889-8529(18)30485-7","article-title":"Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy","volume":"16","author":"Bahn","year":"1987","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R30-20241030","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1530\/eje.1.02201","article-title":"Aquestionnaire survey on the management of graves'orbitopathy in Europe","volume":"155","author":"Perros","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"R31-20241030","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in graves'orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R32-20241030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejrad.2005.03.027","article-title":"Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease","volume":"56","author":"Mayer","year":"2005","journal-title":"Eur J Radiol"},{"key":"R33-20241030","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/archophthalmol.2011.29","article-title":"Rundle and his curve","volume":"129","author":"Bartley","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R34-20241030","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active graves'orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R35-20241030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1507\/endocrj.EJ16-0083","article-title":"Comparison of two different regimens of intravenous methylprednisolone for patients with moderate to severe and active graves'ophthalmopathy:A prospective, randomized controlled trial","volume":"64","author":"He","year":"2017","journal-title":"Endocr J"},{"key":"R36-20241030","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1210\/jc.2013-3919","article-title":"Aprospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves'ophthalmopathy","volume":"99","author":"Zhu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R37-20241030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3892\/etm.2020.9282","article-title":"Comparison of two regimens for patients with thyroid-associated ophthalmopathy receiving intravenous methyl prednisolone:A single center prospective randomized trial","volume":"20","author":"Mu","year":"2020","journal-title":"Exp Ther Med"},{"key":"R38-20241030","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","article-title":"Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with graves'disease is mediated through the insulin-like growth factor I receptor pathway","volume":"170","author":"Pritchard","year":"2003","journal-title":"J Immunol"},{"key":"R39-20241030","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.4049\/jimmunol.178.5.3281","article-title":"Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with graves'disease may carry functional consequences for disease pathogenesis","volume":"178","author":"Douglas","year":"2007","journal-title":"J Immunol"},{"key":"R40-20241030","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","article-title":"Bcells from patients with graves'disease aberrantly express the IGF-1 receptor:Implications for disease pathogenesis","volume":"181","author":"Douglas","year":"2008","journal-title":"J Immunol"},{"key":"R41-20241030","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors:A tale of two antigens implicated in graves'disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J Immunol"},{"key":"R42-20241030","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1210\/en.2019-00055","article-title":"Arrestin-\u03b2-1 physically scaffolds TSH and IGF1 receptors to enable crosstalk","volume":"160","author":"Krieger","year":"2019","journal-title":"Endocrinology"},{"key":"R43-20241030","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/BF03345273","article-title":"Novel aspects of orbital fibroblast pathology","volume":"27","author":"Smith","year":"2004","journal-title":"J Endocrinol Invest"},{"key":"R44-20241030","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev"},{"key":"R45-20241030","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1210\/jc.2004-0716","article-title":"Immunoglobulins from patients with graves'disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R46-20241030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/105072504774193276","article-title":"Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with graves'ophthalmopathy","volume":"14","author":"Marin\u00f3","year":"2004","journal-title":"Thyroid"},{"key":"R47-20241030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/IIO.0000000000000353","article-title":"Teprotumumab:The first approved biologic for thyroid eye disease","volume":"61","author":"Hwang","year":"2021","journal-title":"Int Ophthalmol Clin"},{"key":"R48-20241030","first-page":"115","article-title":"Monthly pulse methylprednisolone therapy is effective in preventing permanent disease progression in secondary progressive multiple sclerosis.","volume":"56","author":"\u00d6zakba\u015f","year":"2019","journal-title":"Noro Psikiyatr Ars"},{"key":"R49-20241030","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00415-016-8183-3","article-title":"Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment:A prospective web-based multi-center study in multiple sclerosis patients with a relapse","volume":"263","author":"Jongen","year":"2016","journal-title":"J Neurol"},{"key":"R50-20241030","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1210\/clinem\/dgac045","article-title":"It takes two to tango:IGF-I and TSH receptors in thyroid eye disease","volume":"107","author":"Girnita","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R51-20241030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000511538","article-title":"Targeting TSH and IGF-1 receptors to treat thyroid eye disease","volume":"9","author":"Neumann","year":"2020","journal-title":"Eur Thyroid J"},{"key":"R52-20241030","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1210\/jc.2016-1315","article-title":"TSH\/IGF-1 receptor cross talk in graves'ophthalmopathy pathogenesis","volume":"101","author":"Krieger","year":"2016","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Oman Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_308_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:41:05Z","timestamp":1787067665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_308_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ojo.ojo_308_23","relation":{},"ISSN":["0974-620X","0974-7842"],"issn-type":[{"value":"0974-620X","type":"print"},{"value":"0974-7842","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"2023-12-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}